Lymphatic cancer, generally referred to as lymphoma, is curable in some types and requires the use of appropriate scientific treatments. Lymphoma can be divided into Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Among them, Hodgkin’s lymphoma is rare but has a higher cure rate, and has become one of the tumors that can be cured by chemotherapy. Its treatment mainly adopts the integrated treatment of chemotherapy and radiotherapy. The MOPP regimen (M azide, O vincristine, P procarbamide, P prednisone) was mainly used in the early stage, with a complete remission rate of 80%, a five-year survival rate of 75%, and a long-term disease-free survival rate of 50%. The ABVD regimen (A doxorubicin, B bleomycin, V vincristine, D dacarbazine), which is now predominantly used, has a better remission rate and five-year disease-free survival than the MOPP regimen. Non-Hodgkin lymphomas have a relatively poor prognosis overall compared to Hodgkin lymphomas. Non-Hodgkin lymphomas include diffuse large B-cell lymphoma, marginal zone lymphoma, follicular lymphoma, condyloma, and peripheral T-cell lymphoma. Among them, diffuse large B-cell lymphoma is an aggressive lymphoma, and after anthracycline-based chemotherapy, only 50% to 60% of the patients end up with long-term disease-free survival. Set-cell lymphoma and peripheral T-cell lymphoma are also aggressive lymphomas with a poorer prognosis and a five-year disease-free survival rate of 41% to 80% after the use of chemotherapeutic agents. On the other hand, marginal zone lymphoma and follicular lymphoma belong to inert lymphoma, which develops more slowly, and chemotherapy and radiotherapy are effective, but not easy to be relieved. Survival after stage I-II radiotherapy and chemotherapy can be up to ten years. Stage III and IV patients also have a median survival of up to 10 years after chemotherapy, although they may relapse several times.